Lexicon Advances LX6171 for Cognitive Disorders into Phase 1b Clinical Trial
Tuesday January 30, 6:00 am ET
THE WOODLANDS, Texas, Jan. 30 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG - News) announced today that it has initiated a Phase 1b clinical trial of LX6171, its oral drug candidate for the treatment of cognitive impairment associated with disorders such as Alzheimer's disease, schizophrenia and vascular dementia. These disorders affect millions of people worldwide, and their prevalence is increasing as the population ages.
"LX6171 was well tolerated at all dose levels studied and obtained good systemic exposure in its initial Phase 1 trial, a single ascending-dose study completed last year, and we are pleased to advance the compound into this next stage of clinical development," said Philip M. Brown, M.D., J.D., vice president of clinical development at Lexicon. "This second clinical trial for LX6171, in addition to our recently commenced Phase 1 trial of LX1031 for irritable bowl syndrome, underscores our focus on developing Lexicon's discoveries into breakthrough treatments for human disease."
The Phase 1b trial is a randomized, double-blind, placebo-controlled, multiple ascending-dose study to further evaluate LX6171's safety, tolerability and pharmacokinetics. LX6171 will be studied in approximately 40 normal healthy volunteers, including a cohort of elderly subjects. Lexicon expects results from this trial in mid-2007.
About LX6171
LX6171 is an oral drug candidate that was generated by Lexicon medicinal chemists and is being developed to treat disorders characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia or vascular dementia. Its target was internally identified as a selective and potent inhibitor of a novel membrane protein that is expressed exclusively in the central nervous system. In an initial Phase 1 trial, LX6171 was well tolerated at all dose levels studied, with no clinically significant changes noted. In preclinical studies, LX6171 demonstrated improved learning and memory in healthy and aged animal models. |
